MCID: LPD008
MIFTS: 63

Lipid Metabolism Disorder

Categories: Genetic diseases, Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 54 15
Disorder of Fatty Acid Metabolism 29 71
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 42 71
Lipid Metabolism, Inborn Errors 43
Fatty Acid Metabolism Disorder 12
Disorder of Lipid Metabolism 58
Dyslipidemias 71

Classifications:

Orphanet: 58  
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:3146
MeSH 43 D008052
ICD10 32 E71.3
UMLS via Orphanet 72 C0154251
Orphanet 58 ORPHA309005
UMLS 71 C0023772 C0154251 C0242339 more

Summaries for Lipid Metabolism Disorder

MedlinePlus : 42 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to hyperlipoproteinemia, type iii and hypolipoproteinemia. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Nifedipine and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 74 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage... more...

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 687, show less)
# Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia, type iii 33.3 LPL LPA LIPC CETP APOE APOB
2 hypolipoproteinemia 33.1 LPL LPA COG2 CETP APOE APOC3
3 abdominal obesity-metabolic syndrome 1 33.1 SERPINE1 PPARG PPARA LPL LEP INS
4 lipodystrophy, familial partial, type 2 32.8 PPARG LEP INS ADIPOQ
5 sitosterolemia 32.8 HMGCR APOB APOA1
6 prediabetes syndrome 32.5 PPARG PPARA LEP INS CRP COG2
7 coronary artery anomaly 31.7 SERPINE1 LPA HMGCR CRP COG2 APOB
8 non-alcoholic steatohepatitis 31.7 PPARG PPARA INS ADIPOQ
9 end stage renal failure 31.6 LEP CRP COG2 APOB ADIPOQ ACE
10 chronic kidney disease 31.5 SERPINE1 LPL LPA LIPC LEP INS
11 arteries, anomalies of 31.4 SERPINE1 LPA LEP INS CRP COG2
12 sleep apnea 31.4 LEP INS CRP APOE APOB ADIPOQ
13 gestational diabetes 31.3 PPARG LEP INS CRP ADIPOQ
14 pre-eclampsia 31.3 SERPINE1 LEP INS CRP ADIPOQ ACE
15 cerebrovascular disease 31.3 SERPINE1 LPL LPA LEP INS CRP
16 peripheral artery disease 31.3 CRP APOE APOB APOA1 ACE
17 hyperandrogenism 31.3 PPARG INS ADIPOQ
18 hyperlipidemia, familial combined, 3 31.3 PPARA LPL LIPC INS COG2 CETP
19 fatty liver disease 31.3 PPARG PPARA LEP INS CRP APOB
20 hypoalphalipoproteinemia 31.3 LIPC APOA1
21 peripheral vascular disease 31.2 SERPINE1 LPA INS HMGCR CRP COG2
22 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.2 LEP INS ADIPOQ
23 anovulation 31.2 LEP INS CRP
24 fatty liver disease, nonalcoholic 1 31.2 PPARA LEP INS ADIPOQ
25 vascular disease 31.1 SERPINE1 PPARG LPL LPA LIPC LEP
26 diabetic neuropathy 31.1 LEP INS ACE
27 aortic aneurysm, familial abdominal, 1 31.1 CRP CETP APOE ACE
28 hyperinsulinism 31.0 SERPINE1 PPARG PPARA LPL LEP INS
29 acute myocardial infarction 31.0 SERPINE1 LPA INS HMGCR CRP APOB
30 leptin deficiency or dysfunction 31.0 PPARG PPARA LPL LEP INS CRP
31 eye disease 31.0 PPARA INS HMGCR CRP APOA1 ACE
32 proteasome-associated autoinflammatory syndrome 1 31.0 PPARG PPARA INS CRP ADIPOQ
33 homocysteinemia 31.0 SERPINE1 CRP APOE
34 acquired immunodeficiency syndrome 31.0 CRP APOE APOB APOA1
35 polycystic ovary syndrome 31.0 LEP INS CRP ADIPOQ
36 retinal vascular disease 31.0 INS CRP ACE
37 amyloidosis 31.0 LPA INS CRP APOE APOA1
38 pancreatitis 30.9 LPL INS CRP APOA5
39 stroke, ischemic 30.9 SERPINE1 LPA HMGCR CRP COG2 APOE
40 sleep disorder 30.9 LEP INS CRP ADIPOQ ACE
41 diabetes mellitus, insulin-dependent 30.9 LPA LEP INS CRP CETP APOB
42 bone resorption disease 30.9 LEP INS CRP
43 lipid storage disease 30.9 PPARG PPARA LEP INS APOB ADIPOQ
44 amyloidosis aa 30.8 LPA CRP APOA1
45 diabetes mellitus, noninsulin-dependent 30.8 SERPINE1 PPARG PPARA LPL LPA LIPC
46 carotid stenosis 30.8 LPA CRP APOE ADIPOQ ACE
47 acanthosis nigricans 30.8 PPARG LEP INS ADIPOQ
48 familial partial lipodystrophy 30.8 PPARG LEP INS ADIPOQ
49 macular degeneration, age-related, 1 30.8 LIPC INS CRP CETP APOE APOB
50 arteriosclerosis 30.8 SERPINE1 PPARG PPARA LPA INS HMGCR
51 heart disease 30.8 SERPINE1 PPARG PPARA LPL LPA LEP
52 atrial fibrillation 30.8 INS HMGCR CRP ACE
53 uremia 30.8 LPL LEP INS CRP APOC3 ACE
54 intermittent claudication 30.8 SERPINE1 LPL CRP ACE
55 huntington disease-like 1 30.8 LPA CETP APOE APOB APOA1
56 defective apolipoprotein b-100 30.7 HMGCR APOE APOB
57 abetalipoproteinemia 30.7 LPL LPA LEP COG2 CETP APOE
58 tangier disease 30.7 PPARG PPARA LPL LPA CETP APOE
59 alzheimer disease 30.7 PPARG PPARA LPL LPA INS HMGCR
60 arcus corneae 30.7 LPA COG2 APOB APOA1
61 osteoporosis 30.7 SERPINE1 PPARG LPA LEP INS HMGCR
62 major depressive disorder 30.7 LEP FADS1 CRP APOE ACE
63 migraine with or without aura 1 30.7 LEP INS CRP ACE
64 cholelithiasis 30.6 LEP INS CRP APOE
65 coronary stenosis 30.6 SERPINE1 LPL CRP CETP APOE APOB
66 dilated cardiomyopathy 30.6 SERPINE1 PPARG PPARA CRP APOE APOB
67 lipoprotein glomerulopathy 30.6 LPA APOE APOB
68 carotid artery disease 30.6 LPA CRP COG2 APOE APOB APOA1
69 hypercholesterolemia, familial, 1 30.6 LPL LPA LIPC INS HMGCR CRP
70 homozygous familial hypercholesterolemia 30.6 LIPC HMGCR APOE APOB APOA1
71 neuroretinitis 30.6 CRP ACE
72 hyperuricemia 30.6 LEP INS CRP APOE APOB
73 apnea, obstructive sleep 30.6 SERPINE1 LEP INS CRP APOE ADIPOQ
74 lecithin:cholesterol acyltransferase deficiency 30.6 LPL APOE APOB APOA1
75 congenital generalized lipodystrophy 30.6 PPARG LEP INS ADIPOQ
76 xanthomatosis 30.6 LPL LPA HMGCR APOE APOB
77 angina pectoris 30.6 LPA INS CRP APOA1 ACE
78 hepatic lipase deficiency 30.6 LPL LIPC APOE APOA1
79 hypobetalipoproteinemia, familial, 1 30.6 COG2 APOC3 APOB APOA5 APOA1
80 systolic heart failure 30.6 CRP ADIPOQ ACE
81 coronary heart disease 1 30.6 SERPINE1 LPL LPA LIPC INS HMGCR
82 idiopathic edema 30.6 PPARG PPARA INS ADIPOQ ACE
83 glucose intolerance 30.5 SERPINE1 PPARG LPL LEP INS CRP
84 silent myocardial infarction 30.5 LPA INS CRP APOB ACE
85 hypertriglyceridemia, familial 30.5 SERPINE1 LPL LIPC INS CETP APOE
86 polyneuropathy 30.5 INS CRP APOA1 ACE
87 nutritional deficiency disease 30.5 LEP CRP ADIPOQ
88 intermediate coronary syndrome 30.5 LPA INS CRP COG2 APOB APOA1
89 hyperglycemia 30.5 SERPINE1 PPARG LPL LEP INS APOB
90 kidney disease 30.5 SERPINE1 PPARG LPA LEP INS HMGCR
91 gallbladder disease 30.5 INS CRP CETP APOE APOB APOA1
92 pulmonary disease, chronic obstructive 30.5 INS HMGCR CRP ACE
93 placenta disease 30.5 INS CRP ADIPOQ
94 familial hyperlipidemia 30.5 SERPINE1 PPARG PPARA LPL LPA LIPC
95 non-alcoholic fatty liver disease 30.4 SERPINE1 PPARG PPARA LPL LEP INS
96 aortic atherosclerosis 30.4 LPL LPA LIPC CETP APOE ADIPOQ
97 familial lipoprotein lipase deficiency 30.4 LPL LIPC APOE APOC3 APOB APOA5
98 heart valve disease 30.4 LPA CRP ACE
99 myocardial infarction 30.4 SERPINE1 PPARG PPARA LPL LPA LIPC
100 atherosclerosis susceptibility 30.4 SERPINE1 PPARG PPARA LPL LPA LIPC
101 portal hypertension 30.4 SERPINE1 INS ACE
102 hypothyroidism 30.4 SERPINE1 LPL LPA LIPC LEP INS
103 pulmonary embolism 30.3 SERPINE1 CRP ACE
104 cardiovascular system disease 30.3 SERPINE1 PPARG PPARA LPL LPA LIPC
105 body mass index quantitative trait locus 11 30.3 SERPINE1 PPARG PPARA LPL LPA LIPC
106 glucose metabolism disease 30.3 SERPINE1 PPARG PPARA LPA LEP INS
107 vascular dementia 30.2 CRP APOE ACE
108 hypertension, essential 30.2 SERPINE1 PPARG PPARA LPL LPA LEP
109 overnutrition 30.1 SERPINE1 PPARG PPARA LPL LEP INS
110 acute insulin response 30.1 INS CRP
111 diabetes mellitus 30.0 SERPINE1 PPARG PPARA LPL LPA LIPC
112 schizophrenia 30.0 PPARA LEP INS CRP APOE ADIPOQ
113 familial hypercholesterolemia 30.0 LPL LPA LIPC INS HMGCR CRP
114 rare dyslipidemia 12.4
115 rare syndromic dyslipidemia 12.2
116 citrullinemia, type ii, neonatal-onset 12.1
117 citrullinemia, classic 11.6
118 gallbladder disease 1 11.5
119 aromatase deficiency 11.3
120 bietti crystalline corneoretinal dystrophy 11.1
121 hypercholesterolemia, familial, 4 11.1
122 hypoalphalipoproteinemia, primary, 1 11.1
123 lipodystrophy, familial partial, type 3 11.1
124 lipodystrophy, familial partial, type 6 11.1
125 hypercholesterolemia, familial, 3 11.1
126 hypobetalipoproteinemia, familial, 2 11.1
127 acyl-coa dehydrogenase, medium-chain, deficiency of 11.1
128 acyl-coa dehydrogenase, short-chain, deficiency of 11.1
129 acyl-coa dehydrogenase, very long-chain, deficiency of 11.1
130 carnitine-acylcarnitine translocase deficiency 11.1
131 gaucher disease, type i 11.1
132 chylomicron retention disease 11.1
133 carnitine palmitoyltransferase i deficiency 11.1
134 tay-sachs disease 11.1
135 barth syndrome 11.1
136 carnitine palmitoyltransferase ii deficiency, infantile 11.1
137 mitochondrial trifunctional protein deficiency 11.1
138 multiple congenital anomalies-hypotonia-seizures syndrome 11.1
139 steroid inherited metabolic disorder 11.1
140 familial combined hyperlipoproteinemia 10.8 LPL APOB APOA1
141 xanthoma disseminatum 10.8 APOE APOB
142 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 10.8
143 acquired generalized lipodystrophy 10.8 LEP INS ADIPOQ
144 moderate and severe traumatic brain injury 10.8 APOE ACE
145 familial lcat deficiency 10.8 APOE APOA1
146 basilar artery insufficiency 10.8 HMGCR COG2 CETP
147 idiopathic recurrent pericarditis 10.8 LEP ADIPOQ
148 hypothalamic obesity 10.8 LEP INS
149 severe nonproliferative diabetic retinopathy 10.8 INS APOB ACE
150 mediastinum teratoma 10.8 CRP ACE
151 corneal degeneration 10.8 LPA COG2 APOB
152 malignant otitis externa 10.8 INS CRP
153 lipodystrophy, congenital generalized, type 2 10.8 PPARG LEP INS
154 obesity-hypoventilation syndrome 10.8 LEP ADIPOQ
155 sex development disorder 10.8 LEP INS ADIPOQ
156 fetal macrosomia 10.8 LEP INS APOB APOA1
157 cardiac tuberculosis 10.8 SERPINE1 CRP
158 acute dacryoadenitis 10.8 CRP ACE
159 adult syndrome 10.8 LEP INS ADIPOQ
160 hypercholesterolemia, familial, 2 10.8 APOE APOB
161 schnyder corneal dystrophy 10.7 HMGCR APOE APOB
162 platelet glycoprotein iv deficiency 10.7 PPARA INS APOE APOB
163 female breast nipple and areola cancer 10.7 APOE ACE
164 lipase deficiency, combined 10.7 LPL LIPC
165 complete generalized lipodystrophy 10.7 PPARG LEP INS ADIPOQ
166 hypertensive retinopathy 10.7 CRP ADIPOQ ACE
167 neurogenic arthropathy 10.7 INS CRP
168 lipodystrophy, congenital generalized, type 1 10.7 PPARG LEP INS ADIPOQ
169 drug allergy 10.7 INS CRP ACE
170 alcoholic cardiomyopathy 10.7 PPARG PPARA ACE
171 aspiration pneumonia 10.7 INS CRP ACE
172 marek disease 10.7 HMGCR ACE
173 autonomic nervous system disease 10.7 INS CRP ACE
174 central sleep apnea 10.7 LEP CRP ACE
175 nodular nonsuppurative panniculitis 10.7 LIPC CRP
176 alzheimer disease 5 10.7 APOE ACE
177 chronic orbital inflammation 10.7 CRP ACE
178 acute cystitis 10.7 INS CRP ACE
179 ischemic colitis 10.7 SERPINE1 CRP ACE
180 multiple cranial nerve palsy 10.7 CRP ACE
181 mineral metabolism disease 10.7 INS CRP ACE
182 vein disease 10.7 SERPINE1 INS CRP
183 maturity-onset diabetes of the young 10.7 PPARG LPL INS CRP APOC3
184 anterior scleritis 10.7 CRP ACE
185 lysosomal storage disease 10.7 PPARA LEP INS ADIPOQ
186 posterior scleritis 10.7 CRP ACE
187 pericarditis 10.7 LEP CRP ADIPOQ ACE
188 tolosa-hunt syndrome 10.7 CRP ACE
189 pulmonary artery disease 10.7 SERPINE1 CRP ACE
190 ureteral disease 10.7 SERPINE1 CRP ACE
191 amyloidosis, familial visceral 10.7 APOE APOC3 APOA1
192 heart conduction disease 10.7 INS CRP ACE
193 aortic valve disease 2 10.7 LPA CRP APOB ACE
194 prader-willi syndrome 10.7 LEP INS COG2 APOA1 ADIPOQ
195 urinary tract obstruction 10.7 SERPINE1 CRP ACE
196 cerebral atherosclerosis 10.7 LPA CRP APOE APOA1 ACE
197 granulomatous angiitis 10.7 CRP ACE
198 disease of mental health 10.7 LEP INS CRP APOE ACE
199 patent foramen ovale 10.7 SERPINE1 LPA CRP ACE
200 nontuberculous mycobacterial lung disease 10.6 LEP ADIPOQ
201 bone remodeling disease 10.6 LEP INS CRP
202 livedoid vasculitis 10.6 SERPINE1 LPA
203 critical illness polyneuropathy 10.6 INS CRP
204 fibromyalgia 10.6 LEP INS CRP
205 hyperlipoproteinemia, type iv 10.6 LPL LPA APOE APOC3 APOB APOA5
206 generalized atherosclerosis 10.6 LPA INS CRP COG2 APOE APOB
207 maturity-onset diabetes of the young, type 1 10.6 PPARA LEP INS CRP APOC3 ADIPOQ
208 muscular disease 10.6 LEP INS HMGCR CRP ACE
209 hyperalphalipoproteinemia 1 10.6 LPL LIPC CETP APOE APOC3 APOB
210 glycogen storage disease 10.6 LPL INS CRP APOA5
211 intracranial berry aneurysm 10.6 HMGCR CRP APOE
212 hyperlipoproteinemia, type v 10.6 LPL INS HMGCR APOE APOC3 APOB
213 d-bifunctional protein deficiency 10.6
214 disorder of branched-chain amino acid metabolism 10.6
215 optic papillitis 10.6 CRP ACE
216 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.6 SERPINE1 PPARG PPARA LEP INS CRP
217 body mass index quantitative trait locus 1 10.6
218 aortic disease 10.6 CRP APOE ACE
219 granulomatous hepatitis 10.6 CRP ACE
220 hypopituitarism 10.6 LEP INS CRP
221 endocrine pancreas disease 10.6 SERPINE1 PPARG PPARA LPL LEP INS
222 cholesterol embolism 10.6 CRP ACE
223 neurosarcoidosis 10.5 CRP ACE
224 post-traumatic stress disorder 10.5 CRP APOE ADIPOQ
225 potter's syndrome 10.4 INS ACE
226 tetralogy of fallot 10.4 CRP APOE ADIPOQ ACE
227 microvascular complications of diabetes 3 10.4
228 microvascular complications of diabetes 4 10.4
229 microvascular complications of diabetes 6 10.4
230 microvascular complications of diabetes 7 10.4
231 acquired metabolic disease 10.4 SERPINE1 PPARG PPARA LPL LEP INS
232 carnitine deficiency, systemic primary 10.4
233 3-hydroxyacyl-coa dehydrogenase deficiency 10.4
234 multiple acyl-coa dehydrogenase deficiency 10.4
235 succinyl-coa:3-oxoacid-coa transferase deficiency 10.4
236 maple syrup urine disease 10.4
237 methylmalonic aciduria due to methylmalonyl-coa mutase deficiency 10.4
238 methylmalonic aciduria, cbla type 10.4
239 methylmalonic aciduria, cblb type 10.4
240 carnitine palmitoyltransferase ii deficiency, myopathic, stress-induced 10.4
241 peroxisomal acyl-coa oxidase deficiency 10.4
242 3-hydroxy-3-methylglutaryl-coa synthase-2 deficiency 10.4
243 carnitine palmitoyltransferase ii deficiency, lethal neonatal 10.4
244 hyperinsulinemic hypoglycemia, familial, 4 10.4
245 mitochondrial complex i deficiency, nuclear type 20 10.4
246 branched-chain keto acid dehydrogenase kinase deficiency 10.4
247 peroxisomal fatty acyl-coa reductase 1 disorder 10.4
248 peroxisomal beta-oxidation disorder 10.4
249 transient neonatal multiple acyl-coa dehydrogenase deficiency 10.4
250 disorder of fatty acid oxidation and ketogenesis 10.4
251 acyl-coa dehydrogenase deficiency 10.4
252 metabolic disease due to other fatty acid oxidation disorder 10.4
253 disorder of carnitine cycle and carnitine transport 10.4
254 multiple acyl-coa dehydrogenase deficiency, mild type 10.4
255 multiple acyl-coa dehydrogenase deficiency, severe neonatal type 10.4
256 disorder of ketolysis 10.4
257 disorder of fatty acid oxidation and ketone body metabolism 10.4
258 leukodystrophy, hypomyelinating, 3 10.3 APOB APOA1
259 microvascular complications of diabetes 5 10.3
260 obsolete: combined hyperlipidemia 10.3
261 huntington disease-like 2 10.3
262 rapidly involuting congenital hemangioma 10.3
263 inherited metabolic disorder 10.2 PPARG PPARA LPL LPA LEP INS
264 rheumatoid arthritis 10.2
265 huntington disease-like 3 10.2
266 rickets 10.2
267 immune deficiency disease 10.2
268 neuropathy 10.2
269 hypoglycemia 10.2
270 impotence 10.1
271 hyperthyroidism 10.1
272 periodontitis 10.1
273 body mass index quantitative trait locus 9 10.1
274 body mass index quantitative trait locus 8 10.1
275 body mass index quantitative trait locus 4 10.1
276 body mass index quantitative trait locus 10 10.1
277 body mass index quantitative trait locus 7 10.1
278 body mass index quantitative trait locus 12 10.1
279 body mass index quantitative trait locus 14 10.1
280 body mass index quantitative trait locus 18 10.1
281 body mass index quantitative trait locus 19 10.1
282 body mass index quantitative trait locus 20 10.1
283 myositis 10.1
284 thrombosis 10.1
285 nephrotic syndrome 10.1
286 major affective disorder 8 10.1
287 major affective disorder 9 10.1
288 bipolar disorder 10.1
289 glomerulonephritis 10.0
290 autoimmune disease 10.0
291 hyperlipoproteinemia, type i 10.0
292 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
293 bone mineral density quantitative trait locus 8 10.0
294 bone mineral density quantitative trait locus 15 10.0
295 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
296 chlamydia 10.0
297 aortic aneurysm 10.0
298 lichen planus 10.0
299 cytokine deficiency 10.0
300 amyotrophic lateral sclerosis 1 10.0
301 thrombophilia due to thrombin defect 10.0
302 arterial calcification, generalized, of infancy, 1 10.0
303 cystic fibrosis 10.0
304 lysosomal acid lipase deficiency 10.0
305 aging 10.0
306 human immunodeficiency virus type 1 10.0
307 chlamydia pneumonia 10.0
308 sensorineural hearing loss 10.0
309 lymphocytic leukemia 10.0
310 dementia 10.0
311 constipation 10.0
312 transient cerebral ischemia 10.0
313 lateral sclerosis 10.0
314 macular retinal edema 10.0
315 peripheral nervous system disease 10.0
316 osteoarthritis 10.0
317 arthritis 10.0
318 aneurysm 10.0
319 liver disease 10.0
320 neurofibromatosis, type ii 9.9
321 colorectal cancer 9.9
322 nephrolithiasis, calcium oxalate 9.9
323 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
324 periodontitis, chronic 9.9
325 yemenite deaf-blind hypopigmentation syndrome 9.9
326 hyperphosphatemia 9.9
327 dry eye syndrome 9.9
328 dermatomyositis 9.9
329 nasopharyngitis 9.9
330 conn's syndrome 9.9
331 severe pre-eclampsia 9.9
332 alcohol use disorder 9.9
333 hypogonadism 9.9
334 thrombophilia 9.9
335 antiphospholipid syndrome 9.9
336 infertility 9.9
337 hypogonadotropism 9.9
338 diabetic macular edema 9.9
339 growth hormone deficiency 9.9
340 hypoxia 9.9
341 gaucher's disease 9.9
342 47,xyy 9.9
343 alcohol dependence 9.9
344 hepatitis c virus 9.9
345 gout 9.9
346 dermatitis 9.9
347 acute pancreatitis 9.9
348 pustulosis of palm and sole 9.9
349 psoriasis 9.9
350 hepatocellular carcinoma 9.8
351 renal cell carcinoma, nonpapillary 9.8
352 ige responsiveness, atopic 9.8
353 leukemia, chronic lymphocytic 9.8
354 prostate cancer 9.8
355 scleroderma, familial progressive 9.8
356 helicobacter pylori infection 9.8
357 psoriatic arthritis 9.8
358 anxiety 9.8
359 hermansky-pudlak syndrome 2 9.8
360 intraocular pressure quantitative trait locus 9.8
361 graft-versus-host disease 9.8
362 tendinopathy 9.8
363 deficiency anemia 9.8
364 tendinitis 9.8
365 exanthem 9.8
366 inflammatory bowel disease 9.8
367 hypogonadotropic hypogonadism 9.8
368 osteomalacia 9.8
369 open-angle glaucoma 9.8
370 spondyloarthropathy 9.8
371 allergic hypersensitivity disease 9.8
372 hemosiderosis 9.8
373 hyperparathyroidism 9.8
374 eclampsia 9.8
375 cholesterol ester storage disease 9.8
376 mental depression 9.8
377 hepatitis c 9.8
378 rectum cancer 9.8
379 hepatitis b 9.8
380 hepatitis 9.8
381 iron metabolism disease 9.8
382 iga glomerulonephritis 9.8
383 skin disease 9.8
384 thyroid gland disease 9.8
385 human immunodeficiency virus infectious disease 9.8
386 hemolytic anemia 9.8
387 inferior myocardial infarction 9.8
388 thyroiditis 9.8
389 cataract 9.8
390 alopecia 9.8
391 myotonic dystrophy 9.8
392 antisynthetase syndrome 9.8
393 frontal fibrosing alopecia 9.8
394 polymyositis 9.8
395 depression 9.8
396 autonomic dysfunction 9.8
397 rare hereditary hemochromatosis 9.8
398 recurrent acute pancreatitis 9.8
399 pik3ca-related overgrowth syndrome 9.8
400 complications after hematopoietic stem cell transplantation 9.8
401 premature aging 9.8
402 glomerular disease 9.8
403 lipoid congenital adrenal hyperplasia 9.8
404 retinitis pigmentosa 9.8
405 retinitis 9.8
406 rhinitis 9.8
407 subacute thyroiditis 9.8
408 fish-eye disease 9.7
409 celiac disease 1 9.7
410 cephalin lipidosis 9.7
411 gaucher disease, type ii 9.7
412 ichthyosis, congenital, autosomal recessive 4b 9.7
413 pancreatic agenesis 1 9.7
414 pycnodysostosis 9.7
415 myoglobinuria, recurrent 9.7
416 lipodystrophy, familial partial, type 7 9.7
417 ichthyosis prematurity syndrome 9.7
418 respiratory allergy 9.7
419 autosomal recessive congenital ichthyosis 9.7
420 short bowel syndrome 9.7
421 multicentric reticulohistiocytosis 9.7
422 hepatic coma 9.7
423 hepatic encephalopathy 9.7
424 kwashiorkor 9.7
425 viral hepatitis 9.7
426 sphingolipidosis 9.7
427 pancreas disease 9.7
428 pneumonia 9.7
429 polyhydramnios 9.7
430 biliary tract disease 9.7
431 hypereosinophilic syndrome 9.7
432 muscular lipidosis 9.7
433 atrial standstill 1 9.7
434 breast cancer 9.7
435 cardiac conduction defect 9.7
436 fibrosis of extraocular muscles, congenital, 1 9.7
437 systemic lupus erythematosus 9.7
438 down syndrome 9.7
439 ataxia-telangiectasia 9.7
440 myasthenia gravis 9.7
441 chanarin-dorfman syndrome 9.7
442 adrenoleukodystrophy 9.7
443 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 9.7
444 ichthyosis, x-linked 9.7
445 ataxia and polyneuropathy, adult-onset 9.7
446 branchiootic syndrome 1 9.7
447 chorea, childhood-onset, with psychomotor retardation 9.7
448 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
449 renal fibrosis 9.7
450 myoglobinuria 9.7
451 osteonecrosis 9.7
452 silicosis 9.7
453 ovarian disease 9.7
454 respiratory failure 9.7
455 primary biliary cirrhosis 9.7
456 telangiectasis 9.7
457 choreatic disease 9.7
458 cholestasis 9.7
459 toxic shock syndrome 9.7
460 dumping syndrome 9.7
461 rheumatic disease 9.7
462 ichthyosis 9.7
463 enthesopathy 9.7
464 tic disorder 9.7
465 immune system disease 9.7
466 acute kidney failure 9.7
467 ischemia 9.7
468 systemic scleroderma 9.7
469 myopathy 9.7
470 diffuse glomerulonephritis 9.7
471 liver cirrhosis 9.7
472 congestive heart failure 9.7
473 connective tissue disease 9.7
474 herpes simplex 9.7
475 lupus erythematosus 9.7
476 encephalitis 9.7
477 asah1-related disorders 9.7
478 48,xyyy 9.7
479 adrenomyeloneuropathy 9.7
480 dentinogenesis imperfecta type 2 9.7
481 lipogranulomatosis 9.7
482 lymphosarcoma 9.7
483 neonatal adrenoleukodystrophy 9.7
484 encephalopathy 9.7
485 hyperaldosteronism, familial, type i 9.7
486 spondyloarthropathy 1 9.7
487 alopecia, androgenetic, 1 9.7
488 aortic valve disease 1 9.7
489 blood group--newfoundland 9.7
490 coronary artery dissection, spontaneous 9.7
491 creatine phosphokinase, elevated serum 9.7
492 multiple sclerosis 9.7
493 hashimoto thyroiditis 9.7
494 cholestasis, intrahepatic, of pregnancy, 1 9.7
495 renal failure, progressive, with hypertension 9.7
496 parkinson disease, late-onset 9.7
497 platelet aggregation, spontaneous 9.7
498 sarcoidosis 1 9.7
499 small cell cancer of the lung 9.7
500 neural tube defects 9.7
501 trichorhinophalangeal syndrome, type i 9.7
502 triiodothyronine receptor auxiliary protein 9.7
503 adrenocortical carcinoma, hereditary 9.7
504 alstrom syndrome 9.7
505 takayasu arteritis 9.7
506 autism 9.7
507 sitosterolemia 1 9.7
508 lung cancer 9.7
509 cerebrotendinous xanthomatosis 9.7
510 coloboma, ocular, autosomal recessive 9.7
511 hemihyperplasia, isolated 9.7
512 familial mediterranean fever 9.7
513 pancreatic cancer 9.7
514 sea-blue histiocyte disease 9.7
515 short syndrome 9.7
516 graves disease 1 9.7
517 arts syndrome 9.7
518 prostatic hyperplasia, benign 9.7
519 leukemia, acute myeloid 9.7
520 hyperinsulinemic hypoglycemia, familial, 2 9.7
521 autoimmune lymphoproliferative syndrome 9.7
522 hyperlipidemia, familial combined, 1 9.7
523 citrullinemia, type ii, adult-onset 9.7
524 sickle cell anemia 9.7
525 high density lipoprotein cholesterol level quantitative trait locus 14 9.7
526 rippling muscle disease 2 9.7
527 bone mineral density quantitative trait locus 3 9.7
528 creatinine clearance quantitative trait locus 9.7
529 resting heart rate, variation in 9.7
530 endometrial cancer 9.7
531 ovarian hyperstimulation syndrome 9.7
532 aspirin resistance 9.7
533 carney complex variant 9.7
534 preterm premature rupture of the membranes 9.7
535 high density lipoprotein cholesterol level quantitative trait locus 6 9.7
536 cavitary optic disc anomalies 9.7
537 kawasaki disease 9.7
538 diabetes mellitus, ketosis-prone 9.7
539 leukemia, acute lymphoblastic 9.7
540 lipodystrophy, congenital generalized, type 4 9.7
541 leukoencephalopathy with dystonia and motor neuropathy 9.7
542 muscle hypertrophy 9.7
543 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
544 hyperprolactinemia 9.7
545 cholangiocarcinoma 9.7
546 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
547 hydrops, lactic acidosis, and sideroblastic anemia 9.7
548 fetal akinesia deformation sequence 2 9.7
549 fetal akinesia deformation sequence 3 9.7
550 pulmonary hypertension 9.7
551 adrenal cortical carcinoma 9.7
552 hemophagocytic lymphohistiocytosis 9.7
553 tick-borne encephalitis 9.7
554 hypophosphatemia 9.7
555 female breast cancer 9.7
556 vitamin b12 deficiency 9.7
557 diffuse large b-cell lymphoma 9.7
558 androgenic alopecia 9.7
559 atrioventricular block 9.7
560 limb ischemia 9.7
561 colorectal adenoma 9.7
562 colon adenoma 9.7
563 autism spectrum disorder 9.7
564 sexual disorder 9.7
565 cardiac arrest 9.7
566 lymphoproliferative syndrome 9.7
567 salmonellosis 9.7
568 isolated growth hormone deficiency 9.7
569 progressive familial intrahepatic cholestasis 9.7
570 intrahepatic cholestasis of pregnancy 9.7
571 bone disease 9.7
572 type 1 diabetes mellitus 13 9.7
573 migraine with aura 9.7
574 trypanosomiasis 9.7
575 pinta disease 9.7
576 thalassemia 9.7
577 bacterial infectious disease 9.7
578 mastitis 9.7
579 prostatic hypertrophy 9.7
580 pyelonephritis 9.7
581 diphtheria 9.7
582 infant gynecomastia 9.7
583 diabetic angiopathy 9.7
584 protein-energy malnutrition 9.7
585 coronary thrombosis 9.7
586 gastroparesis 9.7
587 esophagitis 9.7
588 inflammatory spondylopathy 9.7
589 chagas disease 9.7
590 bile reflux 9.7
591 male infertility 9.7
592 leukemia 9.7
593 hepatitis a 9.7
594 hemolytic-uremic syndrome 9.7
595 acute leukemia 9.7
596 gynecomastia 9.7
597 quadriplegia 9.7
598 diarrhea 9.7
599 hyperinsulinemic hypoglycemia 9.7
600 biliary atresia 9.7
601 extrahepatic cholestasis 9.7
602 beriberi 9.7
603 amenorrhea 9.7
604 childhood type dermatomyositis 9.7
605 prostatitis 9.7
606 aggressive periodontitis 9.7
607 methylmalonic acidemia 9.7
608 angioedema 9.7
609 keratosis 9.7
610 retinal vein occlusion 9.7
611 calcinosis 9.7
612 cholecystitis 9.7
613 exostosis 9.7
614 autoimmune hepatitis 9.7
615 motor neuron disease 9.7
616 post-thrombotic syndrome 9.7
617 relapsing-remitting multiple sclerosis 9.7
618 acromegaly 9.7
619 psychotic disorder 9.7
620 bilirubin metabolic disorder 9.7
621 prostatic adenoma 9.7
622 food allergy 9.7
623 gingivitis 9.7
624 lipomatosis 9.7
625 complex regional pain syndrome 9.7
626 mood disorder 9.7
627 histiocytosis 9.7
628 lactic acidosis 9.7
629 granuloma annulare 9.7
630 insulinoma 9.7
631 mediastinal lipomatosis 9.7
632 adrenal cortical adenocarcinoma 9.7
633 gastritis 9.7
634 histiocytoma 9.7
635 fibrous histiocytoma 9.7
636 seminoma 9.7
637 hypokalemia 9.7
638 intrahepatic cholangiocarcinoma 9.7
639 arteriosclerosis obliterans 9.7
640 intestinal disease 9.7
641 schizoaffective disorder 9.7
642 inflammatory breast carcinoma 9.7
643 adenoma 9.7
644 spondylitis 9.7
645 hepatoblastoma 9.7
646 b-cell lymphoma 9.7
647 peptic ulcer disease 9.7
648 muscular atrophy 9.7
649 cocaine abuse 9.7
650 retinal degeneration 9.7
651 ulcerative colitis 9.7
652 duodenitis 9.7
653 vasculitis 9.7
654 atrophic gastritis 9.7
655 keratoconjunctivitis 9.7
656 noma 9.7
657 irritable bowel syndrome 9.7
658 hypervitaminosis d 9.7
659 atp8b1 deficiency 9.7
660 hypertrophic cardiomyopathy 9.7
661 insr-related severe syndromic insulin resistance 9.7
662 lmna-related dilated cardiomyopathy 9.7
663 mitochondrial disorders 9.7
664 sickle cell disease 9.7
665 acute mountain sickness 9.7
666 bronchopulmonary dysplasia 9.7
667 chronic graft versus host disease 9.7
668 granulocytopenia 9.7
669 splenomegaly 9.7
670 sudden sensorineural hearing loss 9.7
671 testicular seminoma 9.7
672 cryptogenic cirrhosis 9.7
673 brain injury 9.7
674 hypotonia 9.7
675 infantile hypotonia 9.7
676 spinal cord injury 9.7
677 differentiated thyroid carcinoma 9.7
678 cerebrofacial arteriovenous metameric syndrome 9.7
679 inflammatory myopathy with abundant macrophages 9.7
680 ciliopathy 9.7
681 idiopathic nephrotic syndrome 9.7
682 familial intrahepatic cholestasis 9.7
683 complication after organ transplantation 9.7
684 rare surgical neurologic disease 9.7
685 pediatric systemic lupus erythematosus 9.7
686 intravascular large b-cell lymphoma 9.7
687 thyroid carcinoma 9.7

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN): (showing 2, show less)


Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26 (showing 2, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACE ADIPOQ APOA1 APOA5 APOB APOE
2 cardiovascular system MP:0005385 10.26 ACE ADIPOQ APOA1 APOB APOE CRP
3 growth/size/body region MP:0005378 10.21 ACE ADIPOQ APOB APOE COG2 HMGCR
4 adipose tissue MP:0005375 10.15 ACE ADIPOQ APOE INS LEP LPL
5 endocrine/exocrine gland MP:0005379 10.11 ACE ADIPOQ APOA1 APOE FADS1 INS
6 immune system MP:0005387 10.11 ACE ADIPOQ APOB APOE CRP FADS1
7 liver/biliary system MP:0005370 10.03 ACE ADIPOQ APOA1 APOB APOE HMGCR
8 integument MP:0010771 9.97 ADIPOQ APOA1 APOE INS LEP LPL
9 mortality/aging MP:0010768 9.97 ACE ADIPOQ APOB APOE COG2 FADS1
10 muscle MP:0005369 9.56 ADIPOQ APOB APOE INS LEP LPL
11 renal/urinary system MP:0005367 9.23 ACE ADIPOQ APOE INS LEP PPARA

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 653, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Mirabegron Approved Phase 4 223673-61-8 9865528
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
6
Nevirapine Approved Phase 4 129618-40-2 4463
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
12
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
13
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
14
Bilberry Approved, Experimental Phase 4
15
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
16
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19 Orange Approved Phase 4
20
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
25
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
26
Calcium polycarbophil Approved Phase 4 126040-58-2
27
Loperamide Approved Phase 4 53179-11-6 3955
28
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
29
Lopinavir Approved Phase 4 192725-17-0 92727
30
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
31
Infliximab Approved Phase 4 170277-31-3
32
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
33
Glyburide Approved Phase 4 10238-21-8 3488
34
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
35
Febuxostat Approved Phase 4 144060-53-7 134018
36
Insulin glargine Approved Phase 4 160337-95-1
37
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
38
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
39
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
40
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
41
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
42
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
43
Dulaglutide Approved, Investigational Phase 4 923950-08-7
44
Insulin aspart Approved Phase 4 116094-23-6 16132418
45
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
46
Insulin detemir Approved Phase 4 169148-63-4 5311023
47
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
48
Histamine Approved, Investigational Phase 4 51-45-6 774
49
Gliclazide Approved Phase 4 21187-98-4 3475
50
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
51
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
52 Coconut Approved Phase 4
53
Empagliflozin Approved Phase 4 864070-44-0
54
Liraglutide Approved Phase 4 204656-20-2 44147092
55
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
56
Tesamorelin Approved, Investigational Phase 4 218949-48-5
57
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
58
deoxycholic acid Approved Phase 4 83-44-3 222528
59
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
60
Methyltestosterone Approved Phase 4 58-18-4 6010